A wearable device that stimulates a nerve just below the knee produces meaningful, statistically significant relief from restless legs syndrome — whether patients use it on its own or add it to their existing medication — according to the first individual-participant-data meta-analysis of the therapy, published in Sleep Medicine. The finding arrives as sleep specialists are already shifting RLS treatment strategy away from long-term dopamine-agonist use, making non-drug options like this one more clinically relevant than they were even a year or two ago.
What Tonic Motor Activation Does
The therapy, known as tonic motor activation or TOMAC, is delivered through an FDA-authorized wearable worn bilaterally below each knee, over the common peroneal nerve. During a roughly 30-minute session — typically timed to the evening hours when RLS symptoms are worst — the device delivers high-frequency electrical stimulation intended to counter the urge to move that defines the disorder, without drugs, needles, or surgery.
Unlike dopamine agonists, the RLS drug class most associated with a well-documented long-term complication called augmentation — in which symptoms actually worsen and spread earlier in the day the longer a patient takes the medication — TOMAC carries no systemic pharmacological exposure at all.
Pooling the Evidence
Prior trials of TOMAC had shown promising results individually, but this analysis is the first to combine raw, patient-level data — rather than just published summary statistics — across multiple studies to test the therapy's effect with more statistical power. The research team pooled data from five studies, including three randomized controlled trials, covering 252 total participants: 69 who used TOMAC as their only RLS treatment (monotherapy) and 183 who used it in combination with their existing medication (adjunctive therapy).
Relative to sham stimulation, TOMAC produced significant reductions on the International RLS Study Group Rating Scale, the standard clinical measure of RLS symptom severity, both as monotherapy (a mean improvement of 3.80 points) and as an add-on to medication (3.39 points). Sleep quality, measured by the Medical Outcomes Study Sleep Problems Index, improved as well — by 9.65 points with TOMAC alone and 8.23 points when combined with medication. All four effects were statistically significant, with the monotherapy sleep-quality improvement in particular showing a strong effect size.
Fitting a Broader Shift in RLS Care
The finding lands amid a wider recalibration in how sleep specialists approach chronic restless legs syndrome. The 2026 Restless Legs Syndrome Foundation treatment algorithm already recommends favoring non-dopaminergic approaches for chronic, persistent disease, reserving dopamine agonists for more selective, limited use. A device with trial-level evidence for working as a standalone therapy — not just an add-on for patients already maxed out on medication — gives clinicians a concrete non-drug option to reach for earlier in that treatment sequence, rather than after augmentation has already become a problem.
What This Means for Patients
For patients with moderate to severe RLS who are wary of starting a dopamine agonist, or who have already experienced augmentation on one, this analysis offers the strongest evidence yet that a nerve-stimulation device can meaningfully reduce symptoms without that risk — including for patients who prefer not to add another medication to their regimen at all. The device is already available by prescription in the United States for medication-refractory RLS.
The therapy isn't a cure, and the pooled trials still represent a modest total sample size by the standards of large drug trials. Patients considering it should talk with a sleep medicine specialist about whether their RLS severity and history — including any prior augmentation with dopaminergic drugs — make them a good candidate for a nerve-stimulation-based approach, either as a first-line option or alongside a lower dose of their current medication.
